Allergy Therapeutics (LSE:AGY) Tariff Resilience Score: 6/10 (As of Jul. 13, 2026)


What is Allergy Therapeutics Tariff Resilience Score?

Allergy Therapeutics LSE:AGY +0.30% Tariff Resilience Score is 6 as of Jul. 13, 2026. The stock has 7 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Allergy Therapeutics ranks better than 91.06% on this metric.

Allergy Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Allergy Therapeutics has Moderate exposure due to reliance on international suppliers for raw materials. Manufacturing is primarily in the UK, with sales across Europe. Historical tariffs have had limited impact, but Brexit-related changes pose risks. Mitigation through alternative suppliers and strong EU market presence.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Allergy Therapeutics might have Average Resilient.

Allergy Therapeutics  (LSE:AGY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Allergy Therapeutics Tariff Resilience Score Related Terms

LSE:AGY vs ZTS, UTHR, VTRS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergy Therapeutics Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
Allergy Therapeutics (LSE:AGY) has a Tariff Resilience Score of 6 as of Jul. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Allergy Therapeutics ranks #92 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Allergy Therapeutics' Tariff Resilience Score too high?
Allergy Therapeutics' current Tariff Resilience Score is 6. Based on the distribution chart, Allergy Therapeutics ranks #92 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Allergy Therapeutics' Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #92 out of 1029 companies for Tariff Resilience Score. This places Allergy Therapeutics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Allergy Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 124% above its estimated fair value. The current Tariff Resilience Score is 6. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current Tariff Resilience Score is 6 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allergy Therapeutics Business Description

Other Exchanges AGYTF:USAHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).